Variable | CSKp (n = 17) | CRKp (n = 31) | Univariate analysis | ||
---|---|---|---|---|---|
Adjusted OR | 95% CI | P-value | |||
Sex (male, n) | 11(65%) | 27(87%) | 0.611 | 0.144—2.596 | 0.502 |
Age (y) (mean ± SD) | 62.71 ± 16.34 | 57.61 ± 14.78 |  |  | 0.306 |
Co- morbidities | |||||
 Diabetes mellitus | 5 (29%) | 9 (29%) | 0.982 | 0.268—3.602 | 0.978 |
 Hypertension | 9 (53%) | 15 (48%) | 0.833 | 0.255—2.724 | 0.763 |
 Coronary heart disease | 1 (6%) | 3 (10%) | 1.714 | 0.164—17.886 | 1 |
 Chronic liver disease | 3(18%) | 6(19%) | 1.120 | 0.242–5.186 | 1 |
 Chronic renal failure | 2 (12%) | 4 (13%) | 1.111 | 0.182—6.796 | 0.909 |
 Solid organ tumor | 4 (24%) | 7 (23%) | 0.948 | 0.233—3.850 | 0.940 |
 HIV | 0 | 0 | NA | NA | NA |
 Surgery in the past medical historya | 3 (18%) | 5 (16%) | 0.897 | 0.186—4.322 | 0.893 |
 Prior healthcare-associated exposure | 7 (41%) | 9 (29%) | 0.584 | 0.169—2.017 | 0.393 |
Prior medicine exposure | |||||
 Glucocorticoid | 7 (41%) | 13 (42%) | 1.032 | 0.311—3.428 | 0.959 |
 Immunosuppressorb | 1 (6%) | 2 (6%) | 1.103 | 0.093—13.135 | 1 |
Prior use of antimicrobials | |||||
 Penicillin | 3 (18%) | 10 (32%) | 2.105 | 0.480—9.237 | 0.318 |
 Second cephalosporin | 1 (6%) | 4 (13%) | 2.240 | 0.228—22.051 | 0.838 |
 extended-spectrum cephalosporins | 7 (41%) | 15 (48%) | 1.224 | 0.351—4.269 | 0.750 |
 Aminoglycosides | 1 (6%) | 3 (10%) | 1.615 | 0.153—17.016 | 1 |
 Quinolones | 1 (6%) | 3 (10%) | 1.615 | 0.153—17.016 | 1 |
 Tigecycline | 0 | 4 (13%) | 0.625 | 0.492—0.795 | 0.613 |
 Imipenem | 1 (6%) | 11(39%) | 8.556 | 0.984—74.408 | 0.064 |
 Meropenem | 1 (6%) | 12 (39%) | 9.882 | 1.141—85.619 | 0.068 |
Ertapenem | 0 | 0 | NA | NA | NA |
 Linezolid | 1 (6%) | 12 (39%) | 9.882 | 1.141—85.619 | 0.068 |
 Glycopeptides Vancomycin | 1 (6%) | 8 (26%) | 5.333 | 0.599—47.468 | 0.216 |
 Teicoplanin | 1 (6%) | 5 (16%) | 2.917 | 0.309—27.560 | 0.333 |
Invasive procedure before | |||||
 Central venous catheterization | 10(59%) | 30 (97%) | 21.000 | 2.294—192.225 | 0.003 |
 Trachea cannula | 4(24%) | 10 (32%) | 1.548 | 0.401—5.971 | 0.525 |
 Tracheotomy | 5(29%) | 12 (39%) | 1.516 | 0.426—5.393 | 0.519 |
 Urinary catheter | 7(41%) | 23 (74%) | 4.107 | 1.168—14.436 | 0.024 |
 stomach tube | 14(82%) | 27 (87%) | 1.446 | 0.283—7.384 | 0.656 |
 Intrathoracic drain | 0(0) | 4 (13%) | 0.614 | 0.485—0.776 | 0.282 |
 Abdominal cavity drainage-tube | 5(29%) | 15 (48%) | 2.250 | 0.639—7.923 | 0.202 |
 External ventricular drainage tube care | 0(0) | 1 (3%) | 0.612 | 0.490—0.765 | 1 |
 Liver function on admission | 5(35%) | 3 (10%) | 0.257 | 0.053—1.252 | 0.079 |
 Renal function on admission | 7(41%) | 4(13%) | 0.275 | 0.071—1.070 | 0.055 |
 APACHE II score on admission | 12.29 ± 7.32 | 9.45 ± 4.60 |  |  | 0.334 |